Although mutations in the kinase domain of CDK4 and CDK6 have not been reported as mechanisms of resistance to CDK4/6i, CDK6 amplification was described in CDK4/6i-resistant breast cancer cell models [27]. Here, CDK4 is linked to breast carcinoma.